Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Refereed |
Title | Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel PlusS-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. |
Journal | Formal name:Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abbreviation:J Clin Oncol ISSN code:1527-7755(Electronic)0732-183X(Linking) |
Domestic / Foregin | Foregin |
Volume, Number, Page | 36(19),pp.1922-1929 |
Papers・Author | Ishigami Hironori, Fujiwara Yoshiyuki, Fukushima Ryoji, Nashimoto Atsushi, Yabusaki Hiroshi, Imano Motohiro, Imamoto Haruhiko, Kodera Yasuhiro, Uenosono Yoshikazu, Amagai Kenji, Kadowaki Shigenori, Miwa Hiroto, Yamaguchi Hironori, Yamaguchi Takuhiro, Miyaji Tempei, Kitayama Joji |
Publication date | 2018/07 |
Papers・Description | Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (<2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 |
DOI | 10.1200/JCO.2018.77.8613 |
PMID | 29746229 |